Compare Mesoblast Limited (MESO) vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $64.59 (market cap $394.18M). The key difference: Mesoblast Limited is far larger — about 4.4× Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033's market cap, and Mesoblast Limited is more actively traded (239,027 versus 84,843). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 for 63 Days on average.
| MESO | SLVO | |
|---|---|---|
Market Cap | $1.75B | $394.18M |
Volume | 239,027 | 84,843 |
Sector | Health | Income / Options Overlay |
52-Week High | $20.96 | $107.41 |
52-Week Low | $13.19 | $61.81 |
Typical Hold Time | 15 Days | 63 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
SLVO trades at $64.59, up 1.62% today but remains in a bearish technical trend, with moving averages signaling continued downward pressure. Financial ratios are not available, limiting fundamental clarity. Recent news highlights the stock crossing below its 50-day moving average and links its performance to silver price declines, indicating sensitivity to commodity markets.
The outlook is cautious due to bearish technicals and commodity volatility. Opportunities exist if silver prices stabilize, but risks include dollar strength and lack of fundamental data. Investors should weigh technical recovery potential against macroeconomic headwinds affecting silver.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →
